Bladder Cancer | Tumor

CURE’s bladder cancer page is a go-to resource for oncology news and updates in the world of bladder cancer. Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in bladder cancer.

Patients With High-Risk Non-Muscle Invasive Bladder Cancer Show Response to Keytruda

October 25th 2018

The immunotherapy agent Keytruda is showing promise for treating non-muscle invasive bladder cancer, according to a recent study.

Those in Remission from Bladder Cancer Report More Positive Experiences

October 23rd 2018

In a recent survey, individuals in remission reported a more positive experience with bladder cancer compared with their counterparts who currently have active disease.

New Research Says Universal Lynch Syndrome Testing Should Be Expanded

October 22nd 2018

While universal screening for Lynch syndrome is currently only recommended for patients with colorectal and endometrial cancers, a new study recently published in The American Journal of Surgical Pathology suggests this for patients with upper tract urothelial carcinoma, too.

Decreasing Opioid Use After Urologic Cancer Surgery

October 8th 2018

Can providers decrease opioid prescriptions after surgery, while still managing care adequately?

Immunotherapy's Role in Advanced Bladder Cancer Continues to Evolve

October 5th 2018

Immunotherapy has been a buzzworthy topic in the field of bladder cancer over the last couple of years. However, according to a Food and Drug Administration (FDA) safety warning, patients with metastatic disease may need to have their treatment altered.

Immunotherapy Researchers Win Nobel Prize

October 2nd 2018

Immunotherapy pioneers James P. Allison, Ph.D., and Tasuku Honjo, M.D., Ph.D., have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.

Chemotherapy Before Surgery: Which Regimen is Best for Invasive Bladder Cancer?

September 27th 2018

Researchers determined that the use of methotrexate, vinblastine, doxorubicin and cisplatin before cystectomy may induce better outcomes for patients with advanced bladder cancer.

Genetic Test Aims to Prevent Over-Treatment, Lower Care Costs in Bladder Cancer

September 26th 2018

A new test that identifies which bladder cancer tumors will become invasive could help reduce health care costs and over-treatment in patients.

Subset of Cells in Bladder Cancer May Hinder Immunotherapy Outcomes

September 3rd 2018

Stromal cells – known to provide structure to one’s organs – found in bladder cancer may explain why some patients do not respond to Opdivo (nivolumab) treatment.

When Less Is More in Bladder Cancer Treatment

September 1st 2018

Some patients eligible for bladder surgery due to cancer may safely opt to preserve the organ.

A Double Whammy to Treat Bladder Cancer

August 31st 2018

After chemotherapy, immunotherapy has become the standard treatment for bladder cancer. Will it ever play a bigger role?

New Test May Identify Those Unlikely to Respond to Popular Bladder Cancer Treatment

August 30th 2018

While there is currently no definitive way to predict who will respond and who will not, researchers at Brighton and Sussex Medical School in the United Kingdom are working on a blood test that could identify about half of those who may not.

A Deeper Look Into a 40-Year-Old Bladder Cancer Treatment: Bacillus Calmette-Guerin

August 23rd 2018

CURE spoke with Matthew Mossanen, M.D., from the Division of Urology at Brigham and Women’s Hospital, about what Bacillus Calmette-Guérin (BCG) is and what patients should know about this treatment option.

Immunotherapy in Bladder Cancer: FDA Updates Labels, Approves Diagnostic Tools

August 17th 2018

The Food and Drug Administration (FDA) updated the prescribing information for two immunotherapy agents – Keytruda (pembrolizumab) and Tecentriq (atezolizumab) – approved to treat patients with locally advanced or metastatic bladder cancer who are not eligible for cisplatin-based therapy.

Two Large Trials Investigate Combination Immunotherapy in Bladder Cancer

July 31st 2018

With five immunotherapy drugs approved in the bladder cancer space, the next question researchers find themselves asking is whether these drugs would work better alone or as part of a combination for patients with metastatic disease.

When Cancer Clusters, Create a Medical Family Tree

July 28th 2018

Creating a medical family tree is helpful. If cancer is common, noting which branches include it can help inform decisions.

Gender Influences Bladder Cancer Survival

July 23rd 2018

Women are more likely to die from bladder cancer earlier on after diagnosis, according to recent study findings published in the European Journal of Cancer. However, after that time frame the risk of death is higher for men.

Pre-Surgical Bladder Cancer Treatment: What's Next

July 16th 2018

Many questions still remain in the treatment of localized bladder cancer, like which patients are best suited to receive neoadjuvant (pre-surgery) chemotherapy – a procedure that could be beneficial to many, but comes with increased toxicity.

Gender May Play a Role in Immunotherapy Efficacy, Further Studies Are Warranted

June 29th 2018

Because little is known about the effect of patients' sex on the efficacy of immune checkpoint inhibitors as cancer treatments, the researchers performed a systematic review and meta-analysis to determine the heterogeneity of immune checkpoint inhibitor efficacy between men and women.

Expert Talks Immunotherapy, Unanswered Questions in Metastatic Bladder Cancer

June 22nd 2018

Immunotherapy is being tested in the second-line setting for metastatic bladder cancer. Pending trial results, the role of chemotherapy for this patient population may change.

Erdafitinib Shows Promise in Advanced FGFR-Positive Bladder Cancer

June 21st 2018

Phase 2 study results showed that patients with metastatic or unresectable, FGFR-positive bladder cancer may have a third-line option for treatment.

FDA Updates Immunotherapy Labels for Bladder Cancer Treatment

June 21st 2018

The FDA has incorporated PD-L1 status into the labels for Keytruda (pembrolizumab) and Tecentriq (atezolizumab) for existing frontline approvals for platinum-ineligible patients with urothelial carcinoma, based on lower overall survival (OS) rates with the PD-1/PD-L1 inhibitors compared with platinum-based chemotherapy for patients with PD-L1–low expressing platinum-eligible urothelial carcinoma.

Contagious Enthusiasm

June 20th 2018

Oncolytic, or engineered, viruses that infect and kill cancer cells are showing promise.

Investigational Drug Shows Promise in Patients with Metastatic Urothelial Cancer

June 5th 2018

Enfortumab vedotin may be a potential novel therapy for patients with locally advanced or metastatic urothelial cancer, according to updated phase 1 study findings presented during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

Monitoring Immunotherapy's Side Effects in Genitourinary Cancers

May 24th 2018

PD-1 and PD-L1 inhibitors are generally well-tolerated, so most patients face little or no issues with the drugs. However, there are still some things to look out for.

Examining Stress and Quality of Life in Bladder Cancer

May 21st 2018

Patients with non-muscle invasive bladder cancer experience high levels of distress, according to one study.

Immunotherapy in GU Cancers: Combinations Are the Next Step

May 4th 2018

Immunotherapy is making landmark change in the treatment of patients with genitourinary (GU) cancers, with bladder cancer being the pioneer in the field, having five FDA-approved checkpoint inhibitors. But kidney cancer is not far behind, with a breakthrough therapy designation granted for a Keytruda (pembrolizumab) combination this past January.

Combination Improves Responses, Misses Survival Endpoint in Bladder Cancer Trial

April 25th 2018

The combination use of Cyramza (ramucirumab) plus docetaxel showed improvements in objective response rate (ORR) and a positive trend in overall survival (OS) among patients with advanced bladder cancer, according to additional results from the phase 3 RANGE trial.

Concurrent Chemo, Immunotherapy Offers Viable Option in Metastatic Bladder Cancer

April 21st 2018

In particular, patients whose tumors have certain genetic mutations may respond especially well to this combination approach.

There Are Multiple Dynamic Biomarkers for Bladder Cancer

April 20th 2018

While there are a few common and well-known checkpoints for bladder cancer, there are also many more than PD-1, PD-L1 and CTLA-4.

NEXT PAGE
PREVIOUS PAGE